sulfasalazine has been researched along with Hypertension in 8 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)." | 7.83 | Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016) |
| "Sulfasalazine was not able to rescue fetal growth, in male or female fetuses." | 5.91 | Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model. ( Beard, S; Binder, NK; Brownfoot, FC; de Alwis, N; Hannan, NJ; Harper, A; Kadife, E; Kaitu'u-Lino, TJ, 2023) |
| "Plasma free metanephrines or urinary fractionated metanephrines are the biochemical tests of choice for the diagnosis of pheochromocytoma as they have greater sensitivity and specificity than catecholamines for pheochromocytoma detection." | 3.96 | Case report of a phantom pheochromocytoma. ( Costelloe, SJ; Joyce, CM; Melvin, A; O'Halloran, DJ; O'Shea, PM, 2020) |
| " Patients treated with leflunomide had increases in BP and a greater risk of incident hypertension compared with patients treated with methotrexate (hazard ratio, 1." | 3.88 | Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, LA; England, BR; George, M; Ibrahim, S; Michaud, K; Mikuls, TR; OʼDell, J; Sauer, B; Teng, CC, 2018) |
| "To compare the risk of incident hypertension between initiators of tumor necrosis factor (TNF)-α inhibitors and initiators of nonbiologic disease modifying antirheumatic drugs (hereafter referred to as nonbiologics) in rheumatoid arthritis patients taking methotrexate monotherapy." | 3.83 | Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. ( Danaei, G; Desai, RJ; Kim, SC; Liao, KP; Schneeweiss, S; Solomon, DH, 2016) |
| "The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)." | 3.83 | Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016) |
| "Sulfasalazine was not able to rescue fetal growth, in male or female fetuses." | 1.91 | Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model. ( Beard, S; Binder, NK; Brownfoot, FC; de Alwis, N; Hannan, NJ; Harper, A; Kadife, E; Kaitu'u-Lino, TJ, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Binder, NK | 1 |
| de Alwis, N | 1 |
| Beard, S | 1 |
| Kadife, E | 1 |
| Harper, A | 1 |
| Kaitu'u-Lino, TJ | 1 |
| Brownfoot, FC | 1 |
| Hannan, NJ | 1 |
| Joyce, CM | 1 |
| Melvin, A | 1 |
| O'Shea, PM | 1 |
| Costelloe, SJ | 1 |
| O'Halloran, DJ | 1 |
| Baker, JF | 1 |
| Sauer, B | 1 |
| Teng, CC | 1 |
| George, M | 1 |
| Cannon, GW | 1 |
| Ibrahim, S | 1 |
| Cannella, A | 1 |
| England, BR | 1 |
| Michaud, K | 1 |
| Caplan, L | 1 |
| Davis, LA | 1 |
| OʼDell, J | 1 |
| Mikuls, TR | 1 |
| Uutela, T | 1 |
| Kautiainen, H | 1 |
| Järvenpää, S | 1 |
| Salomaa, S | 1 |
| Hakala, M | 1 |
| Häkkinen, A | 1 |
| Desai, RJ | 1 |
| Solomon, DH | 1 |
| Schneeweiss, S | 1 |
| Danaei, G | 1 |
| Liao, KP | 1 |
| Kim, SC | 1 |
| Wu, LC | 1 |
| Leong, PY | 1 |
| Yeo, KJ | 1 |
| Li, TY | 1 |
| Wang, YH | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Handler, J | 1 |
| Jewell, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Secondary Event Prevention Using Population Risk Management After PCI[NCT02694185] | 5,269 participants (Actual) | Interventional | 2016-10-01 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiovascular Events (CVEs) such as mortality, myocardial infarction, stroke, or repeat revascularization among IHD patients at 12 months post-PCI and progressive erosive disease demonstrated in patients with rheumatic disease will be monitored. CVEs will be monitored to determine if there is a reduction in the occurrence of those events as a result of the intervention. (NCT02694185)
Timeframe: 1 year
| Intervention | Cardiovascular events (Mean) |
|---|---|
| Experimental Group | 15.2 |
| Control Group | 14.3 |
To establish the cost to implement and maintain the intervention, above the cost of usual care. Incremental Cost Effectiveness (ICE) is the cost to achieve a 10% improvement in PDC, and the cost of CVE prevented. (NCT02694185)
Timeframe: through study completion, an average of 1 year
| Intervention | dollars per patient (Median) |
|---|---|
| Experimental Group | 821.45 |
| Control Group | 893.55 |
Proportion of Days Covered (PDC) is measured by looking at the number of doses of medication a patient has versus days in the month (if a patient has 20 days of medication for a 30 day period their PDC is 20/30, 2/3, or 66.7%). Used to assess the effectiveness of the intervention, PDC will be tested among IHD patients in the year after PCI and among rheumatology clinic patients chronically prescribed DMARDs. (NCT02694185)
Timeframe: 1 year
| Intervention | percentage of days covered (Mean) | ||
|---|---|---|---|
| Anti-platelet | Beta-Blocker | Statin | |
| Control Group | 75.6 | 73.3 | 71.2 |
| Experimental Group | 82.6 | 78.4 | 78.8 |
8 other studies available for sulfasalazine and Hypertension
| Article | Year |
|---|---|
Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model.
Topics: Animals; Blood Pressure; Disease Models, Animal; Female; Humans; Hypertension; Male; Mice; Nitric Ox | 2023 |
Case report of a phantom pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Chromatography, Liquid; Chromogranin A; False Positive React | 2020 |
Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Female; | 2018 |
Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Produc | 2015 |
Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine | 2016 |
Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Case-Control Studies; Celecoxib; Coronary Artery Dis | 2016 |
Hydralazine-induced lupus erythematosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Drug Therapy, Combination; F | 2012 |
Benign intracranial hypertension and ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Eye Manifestations; Female; Humans; Hydrocortisone; Hypertension; Intrac | 1972 |